Speaker Connect
The page you requested required you to login before accessing.
For Customer Service issues or questions, please contact customer service:
Phone: (800) 469-7423
Fax: (800) 584-3615
Email: cscomments@myriad.com
- Menu
- Hereditary Cancers
- Hereditary Cancer Panel
- Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
- Lynch Syndrome (HNPCC), MAP
- Polyposis Syndrome (FAP, AFAP, MAP)
- Hereditary Melanoma
- Hereditary Pancreatic Cancer
- How to Assess Patient Risk
- For Your Practice
- For Your Patients
- For Genetic Counselors
Hereditary Cancer Panel
About myRisk®
Why Myriad?
Pre-Test Tools
Post-Test Tools
Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
Risk Assessment Tools
Lynch Syndrome (HNPCC), MAP
Polyposis Syndrome (FAP, AFAP, MAP)
Hereditary Melanoma
Additional Resources
Hereditary Pancreatic Cancer
Additional Resources
How to Assess Patient Risk
Electronic Patient Identification Tools
Recent Publications
Learning Series NEW!
For Oncologists: A New Interactive Learning program to help implement HCRA in your Practice is now available. Get StartedOncology and Surgery
For Your Practice
Assessing Patient Risk
Continuing Ed
Genetic Testing
For Your Patients
Patient Education and Results
Financial Assistance
Privacy
For Genetic Counselors
For Genetic Counselors
For Your Practice
Additional Resources
- Ovarian Cancer
Ovarian Cancer
About BRACAnalysis CDx™
BRACAnalysis CDx™ (FDA approved BRCA1/2 test) is the companion diagnostic test intended to be used as an aid in treatment decision making for the PARP inhibitor Lynparza™ (olaparib).1- Overview
- Why Test
- Recent Publications
- Frequently Asked Questions
- Learn More About Companion Diagnostics
1. BRACAnalysis CDx™ is an in vitro diagnostic device intended for the qualitative detection and classification of variants in the protein coding regions and intron/exon boundaries of the BRCA1 and BRCA2 genes using genomic DNA obtained from whole blood specimens collected in EDTA. Single nucleotide variants and small insertions and deletions (indels) are identified by polymerase chain reaction (PCR) and Sanger sequencing. Large deletions and duplications in BRCA1 and BRCA2 are detected using multiplex PCR. Results of the test are used as an aid in identifying ovarian cancer patients with deleterious or suspected deleterious germline BRCA variants eligible for treatment with Lynparza™ (olaparib). This assay is for professional use only and is to be performed only at Myriad Genetic Laboratories, a single laboratory site located at 320 Wakara Way, Salt Lake City, UT 84108.Hereditary Ovarian Cancer
Infographic
Video
-
Johnathan Lancaster, M.D., Ph.D. talks about the role of companion diagnostics in advancing personalized medicine.
- Lung Cancer
Lung Cancer
About myPlan™
Request More Info
The Science
Recent PublicationsValidation of a Molecular and Pathological Model for Five-Year Mortality Risk in Patients With Early Stage Lung AdenocarcinomaValidation of a Cell Cycle Progression Score for Five-Year Mortality Risk in Patients with Stage I Lung AdenocarinomaPrognostic Multi-Gene Molecular Assay Might Improve Identification of Pathologic Stage IB Lung Adenocarcinoma Patients at Risk for Recurrence - Melanoma
Melanoma
About Myriad myPath™ Melanoma
Myriad myPath™ Melanoma is a unique molecular test created specifically for difficult-to-diagnose melanoma cases. By analyzing 23 genes, the test provides valuable additive molecular information unavailable from any other method for a more informed diagnosis.The Science
Recent PublicationsPresented at SMR Congress - November 2013The Clinical Impact of a Gene Expression Signature that Differentiates Benign Nevi from Malignant MelanomaRequest More Info
Forms and Materials
Hereditary Melanoma
For patients with a p16 gene mutation, the result of the MELARIS® test enables the development of a patient-specific medical management plan to significantly reduce the risk of cancer. - Prostate Cancer
Prostate Cancer
About Prolaris®
Prolaris® measures the expression level of genes involved with tumor proliferation, providing physicians with unique additional information about a patient’s prostate cancer prognosis and may be used with other clinical factors - providing valuable insight into treatment planning.The Science
Recent PublicationsPrognostic utility of the cell cycle progression (CCP) score generated from needle biopsy in men treated with prostatectomyRequest More Info
- ResultsNow™
ResultsNow™
About ResultsNow™
Myriad ResultsNow™ electronically delivers Myriad test results. Easily view your patient’s test results from anywhere there is an internet connection. View from your office, home, on any hand-held device.Access ResultsNow™
- Order Test Kits
- Hereditary Cancers
- Hereditary Cancer Panel
- Hereditary Breast and Ovarian Cancer Syndrome (HBOC)
- Overview
- HBOC Cancer Risks
- Identifying HBOC Patients
- Ovarian Cancer Patients
- Benefits of BRACAnalysis® Testing
- Medical Management with HBOC
- Sample BRACAnalysis® Test Results
- HBOC Clinical Summaries
- HBOC FAQs
- Prevalence Tables
- BRCA Risk Calculator
- BRACAnalysis® Letters of Medical Necessity
- BRACAnalysis® Large Rearrangement Test (BART)
- BRACAnalysis® Sample Family Letters
- Order Now
- Hereditary Colon and Gynecologic Cancers
- Lynch Syndrome (HNPCC), MAP
- Overview
- Lynch Syndrome and MAP Cancer Risks
- Identifying Patients at Risk for Lynch Syndrome and MAP
- Benefits of COLARIS® Testing
- Managing Patients with Lynch Syndrome or MYH-associated Polyposis (MAP)
- Sample COLARIS® Test Results
- Lynch Syndrome Clinical Summaries
- The Myriad Advantage
- COLARIS® FAQ
- COLARIS® Letters of Medical Necessity
- COLARIS® Sample Family Letters
- MLH1 and MSH2 Prevalence Table
- Polyposis Syndromes (FAP, AFAP, MAP)
- Overview
- Adenomatous Polyposis Syndromes Cancer Risks
- Identifying Patients at Risk for Adenomatous Polyposis Syndromes
- Benefits of COLARIS AP® Testing
- Managing Patients with Adenomatous Polyposis Syndromes
- Sample COLARIS AP® Test Results
- Adenomatous Polyposis Syndromes Clinical Summaries
- COLARIS AP® FAQ
- COLARIS AP® Letters of Medical Necessity
- Sample COLARIS AP® Family Letters
- Order Now
- Lynch Syndrome (HNPCC), MAP
- Hereditary Melanoma
- Overview
- Melanoma and Pancreatic Cancer Risks
- Identifying Patients at Risk for Hereditary Melanoma
- Benefits of Melaris® Testing
- Managing Patients with Hereditary Melanoma Syndrome
- Sample MELARIS® Test Results
- MELARIS® Clinical Summaries
- MELARIS® FAQs
- MELARIS® Letters of Medical Necessity
- MELARIS® Sample Family Letters
- Order Now
- Hereditary Pancreatic Cancer
- How to Assess Patient RiskNEW!
- For Your Practice
- For Your Patients
- For Genetic Counselors
- Ovarian Cancer
- Lung Cancer
- About myPlan™
- The Treatment Dilemma
- Advancing the science of lung care
- Measuring Tumor Agressiveness
- Myriad myPlan™ Lung Cancer measures expression levels of critical cell cycle genes. Combined with pathologic tumor stage, the result is correlated with the 5-year risk of lung cancer death—guiding physicians in making chemotherapy decisions for early-stage patients.
- For Patients
- How to Order a Test
- Information Your Patients Need
- The Science – Recent Publications
- Request More Info
- Forms and Materials
- Order Now
- About myPlan™
- Melanoma
- Prostate Cancer
- ResultsNow™
- Documents and Forms